Sort   by:  
 Page size 
ProteomicsPhosphoproteomics analysis of Selinexor response in AML ex vivo patient samples and cell lines
We used mass spectrometry-based proteomics to perform a phosphoproteomics analysis of selinexor-treated ex vivo AML patient samples (n=20) and 4 AML cell lines (PL-21, NOMO-1, GDM-1 and MV4-11). For quantitative phosphoproteomics, we used a tandem mass tag (TMT)-based approach. Conditions for the TM...
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD017660 | Pride
Lc-msms Selinexor Human Aml 
ProteomicsDeep proteomic and phosphoproteomic profiling of neuroblastoma treated with XPO1 inhibitor Selinexor
Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1 that shuffles cargo proteins with a nuclear export sequence, many of which are essential for cancer growth and cell maintenance, from t...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD026454 | Pride
Tmtpro Phosphoproteome Selinexor Xpo1 Neuroblastoma Proteome 
GenomicsRNA sequencing of neuroblastoma cells treated with selinexor or with XPO1 knockdown
RNA sequencing of neuroblastoma cells treated with selinexor or with XPO1 knockdown
PRJNA741521 | ENA
ProteomicsSpatial proteomics of selinexor, MK-2206 and combination response in AML cells
In order to characterize the dynamics of proteins between different cellular compartments in response to selinexor (XPO1 inhibitor), MK-2206 (Akt inhibitor) an the combination i AML cells, we treated MV4-11 and PL-21 cells for 6 hours with DMSO, 1 uM selinexor, 1 uM MK-2206 or the combination. Each...
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD033527 | Pride
Human Spatial proteomics Aml Lc-ms/ms 
ProteomicsSingle-shot proteome of AML cell lines and AML ex vivo cells upon selinexor treatment
Single-shot proteome analysis of 4 AML cell lines; 2 selinexor sensitive cell lines (GDM-1, MV4-11) and 2 resistant cell lines (NOMO-1 and PL-21) and ex vivo AML cells from 30 patients treated with DMSO (B; before treatment) or 1 uM selinexor (A; after treatment) for 6 hours.
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD033515 | Pride
Human Lc-msms Aml 
GenomicsGene expression profiling of AML cell lines treated with nuclear export inhibitor, selinexor
Gene expression profiling of AML cell lines treated with nuclear export inhibitor, selinexor
PRJNA750399 | ENA
GenomicsGene Expression Profiling in Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines Treated with Selinexor
Gene Expression Profiling in Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines Treated with Selinexor
PRJNA1193560 | ENA
ClinicalSafety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
2126069 | ecrin-mdr-crc
GenomicsGene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicle
Gene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicle
PRJNA566346 | ENA
ClinicalRelative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a checkpoint Inhibitor (CPI); or patients with normal HF, with colorectal cancer...
2329120 | ecrin-mdr-crc
Sort   by:  
 Page size